News: "Aquilon proves the high potential of HP-Betadex in Dry Powder formulation"

A revolution in the efficacy of inhaled drugs

Aquilon Pharma aims to play a disruptive role in the next generation formulation technology for inhaled medication by improving the efficacy of inhaled drug.

About us

With its scientific roots in Liège University, Aquilon Pharma is an independent PharmaTech company, specialized in the improvement of the efficacy of drugs, administered through inhalation.

Aquilon in numbers

dedicated team members

innovative products

€-Million Aquilon valuation

achieved clinical trials

ongoing clinical trials

Our technology

HP-Betadex is one of the selected functional excipients for inhalation. This excipient technology improves both the pharmacology and the lung deposition of existing drugs.

Our portfolio

Aquilon Pharma focuses on asthma, COPD and Nasal. Our formulations are compatible with all devices.

Our latest news

A highly experienced team

The Aquilon Pharma drug development team is working on the technical aspects, such as pharmacology, toxicology, clinical studies, pharmaceutical development, etc.

Our partners

Would you like to be a partner of Aquilon Pharma?

Follow us

Stay up to date by following our media channels for our very latest news

Contact us

Do you have a question? Let's get in touch.